Stromal secreted protein acidic and rich in cysteine expression: A potential target for improved prognosis in patients with pancreatic cancer

Table 3 Clinic-pathological characteristics according to secreted protein acidic and rich in cysteine expression, n (%)/mean ± SD

	Variables	SPARC stroma (+) (n = 41)	SPARC stroma (-) (n = 50)	P value
Age (years)		64.4 ± 9.0	63.1 ± 9.7	0.236
Gender	Male/female	22 (53.7)/19 (46.3)	29 (58.0)/21 (42.0)	0.832
Tumor location	Head/body + tail	23 (56.1)/18 (43.9)	34 (68.0)/16 (32.0)	0.281
Radiologic tumor size (cm)		2.82 ± 1.61	2.69 ± 0.98	0.639
Preoperative CA19-9		293.3 ± 512.0	685.8 ± 2053.7	0.236
Operation	PPPD/DPS/TP	23 (56.1)/17 (41.5)/1 (2.4)	35 (70.0)/14 (28.0)/1 (2.0)	0.491
Tumor differentiation	Well/moderate/poor	9 (22.0)/29 (70.7)/3(7.3)	5 (10.0)/37 (74.0)/8 (16.0)	0.198
LVI	Yes/no	11 (26.8)/30 (73.2)	18 (36.0)/32 (64.0)	0.376
PNI	Yes/no	30 (73.2)/11 (26.8)	37 (74.0)/13 (26.0)	> 0.999
pT stage	T1/T2/T3	15 (36.6)/22 (53.7)/4 (9.8)	25 (28.0)/33 (66.0)/3 (6.0)	0.477
pN stage	N0/N1/N2	16 (39.0)/20 (48.8)/5 (12.2)	23 (46.0)/20 (40.0)/7 (14.0)	0.768
Retrieved LN number		19.3 ± 10.4	19.4 ± 9.8	0.986
Metastatic LN number		1.4 ± 2.3	1.4 ± 1.7	0.934
Adjuvant therapy	Yes/no	33 (80.5)/8 (19.5)	40 (80.0)/10 (20.0)	> 0.999

SPARC: Secreted protein acidic and rich in cysteine; CA19-9: Carbohydrate antigen 19-9; LVI: Lymphovascular invasion; PNI: Perineural invasion; LN: Lymph node; PPPD: Pancreaticoduodenectomy, preserving the pancreatic head; DPS: Disease progression score; TP: Total protein.